OMER: Omeros Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for OMER
Across the 20 sessions after earlier OMER headlines, the stock closed higher 14 times and lower 6 times, with a median move of 6.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | OMER | SPY |
|---|---|---|---|
| Oct 16, 2026 | Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA | -13.8% | -1.1% |
| Sep 22, 2026 | Omeros upgraded by Cantor Fitzgerald with a new price target | +13.8% | -0.0% |
| Aug 13, 2026 | Omeros Corporation Reports Second Quarter 2026 Financial Results | +26.5% | +0.7% |
| Aug 10, 2026 | Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026 | +2.8% | -0.0% |
| Aug 3, 2026 | CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA® | +6.1% | +1.4% |
| Jun 26, 2026 | Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA | -19.1% | -0.7% |
Quantisnow market dataNASDAQ
OMER
Omeros Corporation
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2009
Get push alerts for OMER
Full OMER profile on Quantisnow Follow OMER and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time